<DOC>
	<DOCNO>NCT00003675</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Randomized phase II trial study effectiveness topotecan treating patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Topotecan Treating Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate complete partial remission , hematologic improvement , cytogenic response rate oral topotecan give twice day 5 day versus day 10 day patient myelodysplastic syndrome . II . Evaluate safety toxicity oral topotecan patient . III . Evaluate whether morphologic and/or cytogenetic subset myelodysplastic syndrome respond optimally regimen . IV . Evaluate change percentage bone marrow blast cell patient treatment . V. Evaluate time transformation acute myeloid leukemia ( AML ) death patient population . OUTLINE : This randomize , multicenter study . Patients stratify accord FAB subtype : 1 . Refractory anemia excess blast 2 . Refractory anemia excess blast transformation 3 . Chronic myelomonocytic leukemia 4 . Refractory anemia , refractory anemia ring sideroblast , refractory cytopenia multilineage dysplasia Patients randomize receive oral topotecan either twice daily 5 day daily 10 day . Courses repeat every 21 day . Patients evaluate hematologic response initial 2 course , every 4 course . If partial response hematologic improvement observe , treatment continue disease progression acute myeloid leukemia , relapse , death , irreversible toxicity . Patients achieve complete response receive additional 2 course therapy discontinuation protocol treatment . Patients follow every 3 month 2 year , every year additional 3 year , time progression . PROJECTED ACCRUAL : A total 90 patient ( 45 per arm ) accrue study within 13 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Primary therapyrelated myelodysplastic syndrome : Refractory anemia excess blast Refractory anemia excess blast transformation Chronic myelomonocytic leukemia Refractory anemia , refractory anemia ring sideroblast , refractory cytopenia multilineage dysplasia These patient must also one follow criterion : Greater 4 unit RBCs transfuse within past 3 month OR Platelet count le 50,000/mm3 OR Neutrophil count le 1,000/mm3 AND recent infection require antibiotic PATIENT CHARACTERISTICS : Age : Over 15 Performance status : 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 1.5 mg/dL SGOT great 2 time upper limit normal Renal : Creatinine great 1.5 mg/dL Other : Not pregnant nursing Fertile patient must use effective contraception Free evidence prior cancer least 12 month PRIOR CONCURRENT THERAPY : Biologic therapy : At least 1 month since prior interferon No prior hematopoietic growth factor cytokines except epoetin alfa No concurrent epoetin alfa Chemotherapy : No prior topotecan No prior chemotherapy disease At least 12 month since prior chemotherapy another disease No concurrent chemotherapy Endocrine therapy : At least 1 month since prior corticosteroid No concurrent hormonal therapy diseaserelated condition Concurrent steroid adrenal failure allow No concurrent dexamethasone steroidal antiemetic Radiotherapy : No prior radiotherapy disease At least 12 month since prior radiotherapy another disease Surgery : Not specify Other : No prior cytotoxic therapy ( include lowdose antimetabolite ) disease At least 1 month since prior retinoids</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>refractory cytopenia multilineage dysplasia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>